Wellington Management Group LLP Purchases 70,192 Shares of 4D Molecular Therapeutics, Inc. $FDMT

Wellington Management Group LLP lifted its stake in 4D Molecular Therapeutics, Inc. (NASDAQ:FDMT - Free Report) by 39.6% during the first quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The institutional investor owned 247,471 shares of the company's stock after purchasing an additional 70,192 shares during the quarter. Wellington Management Group LLP owned about 0.53% of 4D Molecular Therapeutics worth $799,000 as of its most recent filing with the Securities & Exchange Commission.

A number of other hedge funds have also recently made changes to their positions in FDMT. Wells Fargo & Company MN boosted its position in shares of 4D Molecular Therapeutics by 40.6% in the 4th quarter. Wells Fargo & Company MN now owns 25,852 shares of the company's stock worth $144,000 after purchasing an additional 7,463 shares in the last quarter. Raymond James Financial Inc. bought a new position in 4D Molecular Therapeutics in the 4th quarter valued at approximately $629,000. MetLife Investment Management LLC boosted its stake in 4D Molecular Therapeutics by 21.7% during the 4th quarter. MetLife Investment Management LLC now owns 35,395 shares of the company's stock valued at $197,000 after purchasing an additional 6,312 shares during the last quarter. Hsbc Holdings PLC boosted its stake in 4D Molecular Therapeutics by 88.3% during the 4th quarter. Hsbc Holdings PLC now owns 34,413 shares of the company's stock valued at $190,000 after purchasing an additional 16,142 shares during the last quarter. Finally, Northern Trust Corp boosted its stake in 4D Molecular Therapeutics by 2.3% during the 4th quarter. Northern Trust Corp now owns 440,665 shares of the company's stock valued at $2,455,000 after purchasing an additional 9,982 shares during the last quarter. 99.27% of the stock is owned by institutional investors.

Wall Street Analyst Weigh In

FDMT has been the subject of a number of research analyst reports. Chardan Capital reiterated a "buy" rating and issued a $25.00 price target on shares of 4D Molecular Therapeutics in a research note on Tuesday, August 12th. Weiss Ratings reissued a "sell (d-)" rating on shares of 4D Molecular Therapeutics in a report on Saturday, August 30th. Barclays decreased their price objective on shares of 4D Molecular Therapeutics from $45.00 to $38.00 and set an "overweight" rating for the company in a report on Friday, May 9th. Roth Capital decreased their target price on shares of 4D Molecular Therapeutics from $44.00 to $38.00 and set a "buy" rating for the company in a research note on Tuesday, August 12th. Finally, The Goldman Sachs Group decreased their target price on shares of 4D Molecular Therapeutics from $51.00 to $44.00 and set a "buy" rating for the company in a research note on Friday, May 9th. Eight equities research analysts have rated the stock with a Buy rating, two have issued a Hold rating and one has assigned a Sell rating to the company. Based on data from MarketBeat.com, 4D Molecular Therapeutics presently has a consensus rating of "Moderate Buy" and an average target price of $30.40.

4D Molecular Therapeutics Price Performance

Shares of NASDAQ:FDMT traded up $0.14 during midday trading on Thursday, hitting $6.61. The company had a trading volume of 646,708 shares, compared to its average volume of 864,883. The company has a market cap of $308.70 million, a price-to-earnings ratio of -1.87 and a beta of 2.86. 4D Molecular Therapeutics, Inc. has a 12-month low of $2.23 and a 12-month high of $17.41. The company has a fifty day moving average of $5.29 and a two-hundred day moving average of $4.24.

4D Molecular Therapeutics (NASDAQ:FDMT - Get Free Report) last posted its quarterly earnings data on Monday, August 11th. The company reported ($0.98) EPS for the quarter, missing the consensus estimate of ($0.88) by ($0.10). The company had revenue of $0.01 million during the quarter, compared to analysts' expectations of $0.52 million. 4D Molecular Therapeutics had a negative return on equity of 40.15% and a negative net margin of 594,375.81%. Research analysts expect that 4D Molecular Therapeutics, Inc. will post -2.84 earnings per share for the current fiscal year.

4D Molecular Therapeutics Company Profile

4D Molecular Therapeutics, Inc, a clinical-stage biotherapeutics company, develops genetic medicines using its therapeutic vector evolution platform in the Netherland and the United States. The company develops a portfolio of genetic medicine product candidates focuses in three therapeutic areas for ophthalmology, cardiology, and pulmonology.